⚡️ Tri-Complex Formation with Endogenous Cyclophilin A

Daraxonrasib (RMC-6236) binds to abundant intracellular chaperone cyclophilin A (CypA). The resulting composite surface exhibits exquisite complementary affinity for the effector-binding switch of active RAS(ON).

This physically shields the oncogene from recruiting RAF and PI3K downstream effectors. In clinical trials with advanced pancreatic ductal adenocarcinoma, 84% of heavily pretreated patients achieved confirmed disease control.

📊 Clinical Oncology Efficacy of Daraxonrasib

: 84% of patients

: 78% of participants

: G12D, G12V, G12R variants

: 2.1x increase vs chemotherapy

🧬 Overturning a 40-Year Oncogenic Dogma